X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
1. Fk 463
2. Fk-463
3. Fk463
4. Micafungin
5. Mycamine
1. 208538-73-2
2. Funguard
3. Mycamine
4. Fk463 Sodium
5. Fk-463
6. Micafungin Na
7. Micafungin Sodium Salt
8. Fk 463
9. Micafungin Sodium [usan]
10. Is1up79r56
11. Chebi:80105
12. Fk463
13. Sodium;[5-[(1s,2s)-2-[(3s,6s,9s,11r,15s,18s,20r,21r,24s,25s,26s)-3-[(1r)-3-amino-1-hydroxy-3-oxopropyl]-11,20,21,25-tetrahydroxy-15-[(1r)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[5-(4-pentoxyphenyl)-1,2-oxazol-3-yl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-6-yl]-1,2-dihydroxyethyl]-2-hydroxyphenyl] Sulfate
14. Mycamine Sodium
15. Funguard (tn)
16. Mycamine (tn)
17. Mcfg
18. Micafungin Sodium- Bio-x
19. Unii-is1up79r56
20. Micafungin Na [vandf]
21. Micafungin Sodium (jan/usan)
22. Micafungin Sodium [jan]
23. Chembl1237070
24. Ex-a4114a
25. Micafungin Sodium [mart.]
26. Micafungin Sodium [who-dd]
27. Micafungin Sodium Salt [mi]
28. Mfcd08067752
29. S4287
30. Ccg-270668
31. Micafungin Sodium [orange Book]
32. Ac-30600
33. Bm164667
34. D02465
35. Q27149252
36. Pneumocandin A0, 1-((4r,5r)-4,5-dihydroxy-n2-(4-(5-(5-(pentyloxy)phenyl)-3-isoxazolyl)benzoyl)-l-ornithine)-4-((4s)-4-hydroxy-4-(4-hydroxy-3-(sulfooxy)phenyl)-l-threonine)-, Monosodium Salt
37. Pneumocandin A0, 1-(4r,5r)-4,5-ihydroxy-2-4-5-4-(pentyloxy)henyl]-3-soxazolyl]enzoyl]--rnithine]-4-(4s)-4-ydroxy-4-4-ydroxy-3-(sulfooxy)henyl]
| Molecular Weight | 1292.3 g/mol |
|---|---|
| Molecular Formula | C56H70N9NaO23S |
| Hydrogen Bond Donor Count | 15 |
| Hydrogen Bond Acceptor Count | 24 |
| Rotatable Bond Count | 18 |
| Exact Mass | 1291.42029497 g/mol |
| Monoisotopic Mass | 1291.42029497 g/mol |
| Topological Polar Surface Area | 521 Ų |
| Heavy Atom Count | 90 |
| Formal Charge | 0 |
| Complexity | 2580 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 15 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Mycamine |
| PubMed Health | Micafungin (Injection) |
| Drug Classes | Antifungal |
| Drug Label | Mycamine is a sterile, lyophilized product for intravenous (IV) infusion that contains micafungin sodium. Micafungin sodium is a semisynthetic lipopeptide (echinocandin) synthesized by a chemical modification of a fermentation product of Coleophoma e... |
| Active Ingredient | Micafungin sodium |
| Dosage Form | Injectable |
| Route | injection; Iv (infusion) |
| Strength | 100mg/vial; 50mg; 50mg/vial |
| Market Status | Prescription |
| Company | Astellas; Fujisawa Hlthcare |
| 2 of 2 | |
|---|---|
| Drug Name | Mycamine |
| PubMed Health | Micafungin (Injection) |
| Drug Classes | Antifungal |
| Drug Label | Mycamine is a sterile, lyophilized product for intravenous (IV) infusion that contains micafungin sodium. Micafungin sodium is a semisynthetic lipopeptide (echinocandin) synthesized by a chemical modification of a fermentation product of Coleophoma e... |
| Active Ingredient | Micafungin sodium |
| Dosage Form | Injectable |
| Route | injection; Iv (infusion) |
| Strength | 100mg/vial; 50mg; 50mg/vial |
| Market Status | Prescription |
| Company | Astellas; Fujisawa Hlthcare |
Mycamine is indicated for:
* Adults, adolescents 16 years of age and elderly:
- treatment of invasive candidiasis;
- treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate;
- prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/l) for 10 or more days.
* Children (including neonates) and adolescents < 16 years of age:
- treatment of invasive candidiasis.
- prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/l) for 10 or more days.
The decision to use Mycamine should take into account a potential risk for the development of liver tumours. Mycamine should therefore only be used if other antifungals are not appropriate.
Antifungal Agents
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)
J02AX05
Market Place
